Cystic Fibrosis Management
Diagnosis and Screening
- Newborn screening is available in all US states since 2010 and is a typical method for diagnosis, along with sweat chloride testing, genetic testing, and clinical manifestations, according to the American Academy of Pediatrics 1
- For inconclusive cases, thorough evaluation with genetic sequencing and deletion/duplication analysis is recommended if fewer than 2 disease-causing variants were noted in newborn screening, as suggested by the American Academy of Pediatrics 1
- Repeat sweat testing is recommended until at least age 8 for CRMS/CFSPID cases, as advised by the American Academy of Pediatrics 1
Infection Management
- For Mycobacterium abscessus complex (MABSC) management, an intensive phase of daily oral macrolide + IV amikacin + IV tigecycline/imipenem/cefoxitin is recommended, followed by a continuation phase of daily oral macrolide + inhaled amikacin + 2-3 additional oral antibiotics, according to the European Respiratory Society 2
- Monotherapy with macrolides should never be used for NTM management, as stated by the European Respiratory Society 2
- Combination antibiotic therapy is often needed to address antibiotic resistance in P. aeruginosa infections, and regular susceptibility testing is necessary to guide therapy, as reported by the European Respiratory Society 3
- Colonization by P. aeruginosa can be diagnosed through methods such as aspiration endotracheal, deep pharyngeal culture, or serological tests, according to the European Respiratory Society 3, 4
- Chronic colonization is defined as the presence of P. aeruginosa in the bronchial tree for at least 6 months, based on at least three positive cultures with intervals of at least one month between them, without signs of infection and tissue damage 3
Treatment and Management
- The American Academy of Pediatrics recommends shared decision-making with patients/families regarding medication use and attention to social determinants of health that may affect treatment adherence 1
- For patients with colonization by P. aeruginosa, a combination of inhaled antibiotics (colistin or tobramycin) and oral ciprofloxacin is recommended to delay the onset of chronic infection, according to the Praxis Medical Insights guideline 5
- Colistin is recommended at a dose of 1 million units twice a day, and tobramycin is recommended at a dose of 300 mg twice a day in cycles of 28 days (alternating) or 80-160 mg twice a day, according to the Praxis Medical Insights guideline 5
- Monthly or at least every 3 months microbiological cultures are recommended for patients without previous evidence of colonization by P. aeruginosa, according to the Praxis Medical Insights guideline 5
- Early therapeutic intervention can delay progressive lung damage or even prevent or delay the onset of chronic infection in patients with cystic fibrosis, especially those with colonization by P. aeruginosa 3